Author:
|
Martí Fàbregas, Joan; Medrano-Martorell, Santiago; Merino, Elisa; Prats Sánchez, Luis; Marín, Rebeca; Delgado Mederos, Raquel; Camps Renom, Pol; Martínez Domeño, Alejandro; Gómez Choco, Manuel; Lara, Lidia; Casado-Naranjo, Ignacio; Cánovas, David; Torres, Maria José; Freijo, María del Mar; Calleja, Ana; Bravo, Yolanda; Cocho, Dolores; Rodríguez-Campello, Ana; Zandio, Beatriz; Fuentes, Blanca; Felipe, Alicia de; Llull, Laura; Maestre, José; Hernández, María; Garcés, Moisés; Arce-Borda, Ana Maria de; Palomeras, Ernest; Rodríguez-Yáñez, Manuel; Díaz-Maroto, Inma; Serrano, Marta; Fernández-Domínguez, Jéssica; Sanahuja Montesinos, Jordi; Purroy Garcia, Francisco; Zedde, Marialuisa; Delgado-Mengual, Jordi; Gich, Ignasi
|
Notes:
|
We investigated whether pre-treatment with statins is associated with surrogate markers of amyloid and hypertensive angiopathies in patients who need to start long-term oral anticoagulation therapy. A prospective multicenter study of patients naive for oral anticoagulants, who had an acute cardioembolic stroke. MRI was performed at admission to evaluate microbleeds, leukoaraiosis and superficial siderosis. We collected data on the specific statin compound, the dose and the statin intensity. We performed bivariate analyses and a logistic regression to investigate variables associated with microbleeds. We studied 470 patients (age 77.5 ± 6.4 years, 43.7% were men), and 193 (41.1%) of them received prior treatment with a statin. Microbleeds were detected in 140 (29.8%), leukoaraiosis in 388 (82.5%) and superficial siderosis in 20 (4.3%) patients. The presence of microbleeds, leukoaraiosis or superficial siderosis was not related to pre-treatment with statins. Microbleeds were more frequent in patients with prior intracerebral hemorrhage (OR 9.7, 95% CI 1.06–90.9) and in those pre-treated antiplatelets (OR 1.66, 95% CI 1.09–2.53). Prior treatment with statins was not associated with markers of bleeding-prone cerebral angiopathies in patients with cardioembolic stroke. Therefore, previous statin treatment should not influence the decision to initiate or withhold oral anticoagulation if these neuroimaging markers are detected.
This study was funded by the Spanish Ministery of Health – Instituto Carlos III, Redes Temáticas de Investigación Cooperativa (INVICTUS PLUS RD16/0019/0010) and Fondo de Investigaciones Sanitarias FI12/00296. The study also received funding from FEDER (Fondo Europeo de Desarrollo Regional). The study was done with the aid of the Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society. |